89bio reports positive topline results from entrigue phase 2 trial of pegozafermin in patients with severe hypertriglyceridemia (shtg)

- trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg qw dose; p

ETNB Ratings Summary

ETNB Quant Ranking